Physician profile
Barbara A Kish
NPI 1902894769
$1,780.17
in general payments reported to CMS, 2019-2025
21 companies · $633 in 2025
The $633 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.12 · 2022: $134 · 2023: $493 · 2024: $489 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $588.91 | 2022-2025 | Epclusa, Biktarvy |
| Viiv Healthcare Company | $212.45 | 2023-2025 | Apretude, Dovato |
| Merck Sharp & Dohme LLC | $152.14 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $146.48 | 2022-2025 | |
| Janssen Biotech, INC. | $81.61 | 2022-2023 | Symtuza |
| Organon LLC | $78.66 | 2023-2025 | Nexplanon, Nuvaring |
| Antares Pharma, INC. | $71.87 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $59.10 | 2024-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.91 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $47.01 | 2025 | Airsupra, Farxiga |
| Xeris Pharmaceuticals, INC. | $45.12 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $39.43 | 2023-2024 | Dexcom G6 Transmitter |
| Halozyme INC | $38.54 | 2023 | |
| Exact Sciences Corporation | $38.06 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.72 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $20.56 | 2025 | Natroba, Spinosad |
| Phadia US INC. | $19.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.65 | 2025 | Fanapt |
| Lilly USA, LLC | $18.56 | 2024 | Mounjaro |
| Novo Nordisk INC | $17.80 | 2025 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $13.48 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Kish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.